SCHEMBL26654126

SCHEMBL26654126

COCOc1ccccc1-c1cc2c(cc(C3CN(C(=O)OC(C)(C)C)C3)n2C(F)F)nn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 2/20 0.37
▸ SMARCA4 P51532 2/20 0.37
▸ PBRM1 Q86U86 2/20 0.37
▸ DGAT2 Q96PD7 3/20 0.35
▸ KLKB1 P03952 1/20 0.35
▸ ALOX5AP P20292 2/20 0.34
▸ FEN1 P39748 2/20 0.34
▸ BACE1 P56817 1/20 0.34
▸ BACE2 Q9Y5Z0 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNA2 P20248 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CCNA1 P78396 1/20 0.34
▸ USP30 Q70CQ3 2/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ PDE4B Q07343 2/20 0.34
▸ PDE4D Q08499 2/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4C Q08493 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25215923 0.80 SMARCA2 (0.39) SMARCA2SMARCA4PBRM1KLKB1CCNT1
SCHEMBL26654056 0.79 SMARCA2 (0.38) SMARCA2SMARCA4PBRM1KLKB1BACE1
SCHEMBL30658000 0.79 SMARCA2 (0.38) SMARCA2SMARCA4PBRM1KLKB1BACE1
SCHEMBL31505531 0.76 CCNT1 (0.41) SMARCA2SMARCA4PBRM1KLKB1BACE1
SCHEMBL26654087 0.75 SMARCA2 (0.52) SMARCA2SMARCA4PBRM1NAMPTIDO1
SCHEMBL31505584 0.74 SMARCA2 (0.37) SMARCA2SMARCA4PBRM1KLKB1CCNT1
SCHEMBL29619456 0.74 SMARCA2 (0.48) SMARCA2SMARCA4PBRM1ALOX5APFEN1
SCHEMBL31294033 0.72 SMARCA2 (0.39) SMARCA2SMARCA4PBRM1
SCHEMBL30632467 0.72 KRAS (0.39) SMARCA2SMARCA4PBRM1PDE4B
SCHEMBL26684887 0.72 KRAS (0.39) SMARCA2SMARCA4PBRM1PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
EP-4522279-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
WO-2023220134-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF BRCA1, VHL, SF3B5 SMARCA2 77/4885SMARCA4 19/4885PBRM1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback